Beam Therapeutics (BEAM) Accumulated Depreciation (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Accumulated Depreciation data on file, last reported at $99.7 million in Q1 2026.

• On a quarterly basis, Accumulated Depreciation rose 28.46% year-over-year to $99.7 million in Q1 2026; TTM through Mar 2026 was $99.7 million, a 28.46% increase from a year earlier, with the FY2025 full-year figure at $94.1 million, up 30.54% from the prior year.
• Accumulated Depreciation for Q1 2026 stood at $99.7 million, up from $94.1 million in the prior quarter.
• Over the last five years, Accumulated Depreciation for BEAM reached as high as $99.7 million in Q1 2026 and fell as low as $19.3 million in Q1 2022.
• Historically, Accumulated Depreciation has averaged $56.9 million across 5 years, with a median of $55.6 million in 2024.
• Across the five-year window, Accumulated Depreciation soared 93.95% in 2022 and rose 28.46% in 2026, its largest moves.
• Year by year, Accumulated Depreciation stood at $30.2 million in 2022, then jumped by 66.33% to $50.2 million in 2023, then jumped by 43.69% to $72.1 million in 2024, then jumped by 30.54% to $94.1 million in 2025, then climbed by 5.95% to $99.7 million in 2026.
• Per Business Quant data, the three most recent Accumulated Depreciation figures were $99.7 million in Q1 2026, $94.1 million in Q4 2025, and $88.6 million in Q3 2025.